Progression of targeted therapy of multiple myeloma bone disease / 白血病·淋巴瘤

ABSTRACT

Multiple myeloma (MM) is a hematological malignancy. Osteolytic lesion is the commonest complication in patients with MM. Skeletal-related events severely affect the survival quantity and prognosis. Current therapeutic approach for the treatment of myeloma bone disease (MBD) is based on the use of bisphosphonates. AS the recent advance in the pathogenesis and therapeutics of MBD,more factors related to this disease are found. In this article important factors related to the pathogenes of MBD and the cytokine targeted therapies are reviewed.